1 of 1
Story summary
- Enlicitide reduced LDL cholesterol by about 60% versus placebo in a phase three trial of 2,909 at-risk patients.
- The findings suggest enlicitide could help millions in the United States who struggle to control cholesterol.
- Dr. Ann Marie Navar led the study, funded by Merck & Co. Inc, and published in The New England Journal of Medicine.
- If approved by the FDA, enlicitide may enhance prevention of heart attacks and strokes.
